lists patented inventions available for sale or licensing. Inventors can list their patented inventions (or patent pending) for sale. New inventions for sale are added on a daily basis !
Home    List your patent    My account     Help     Support us    


[Category : - HEALTH]
[Viewed 72 times]

Haemorrhage or severe blood loss leads to approximately 2 million deaths every year globally ( 2018). Various solutions are available to clinicians to manage haemostasis; however market research indicates substantial room for improvements in areas of cost, shelf- life, speed of haemostasis, biocompatibility (decrease of side-effects like immune response and scarring), and biodegradability.

ANU has developed a new non-oxidized cellulose-based nanofiber (CNF) that has demonstrated superior haemostatic properties against both Surgicel® and Combat Gauze®. The material can be fabricated using an environmentally friendly, cost-effective and scalable ball- milling process and can be administered as both a gel and a sponge.
Potential benefits

A series of clinically relevant in-vitro (thromboelastometry) and in-vivo (terminal liver injury model and subcutaneous implantation model in mice) tests provide compelling data on superiority of our technology over current gold standards Surgicel® and Combat Gauze®.
> Speed: Faster clotting times
> Firmness: Increased clot firmness
> Reduced blood loss: Reduced blood loss by > 2x in- vivo (mice) vs Surgicel®.
> Biocompatibility: Does not scar, degrades slowly over time.
> Special Cases: Demonstrated effectiveness against both heparinised and thrombocytopenia patient blood samples.

Potential applications
> Vascular surgery
> ENT surgery
> Thrombocytopenia haemostasis
> Heparinised patient haemostasis
> External wound healing
> Combat first-aid

Financial information

Our researcher has moved on to another project and we are not in a position to further develop this technology.

The technology is currently at TRL-4 with the last work done on non-terminal animal models. ANU is looking for interest for sale of the IP to a group seeking to bolster their existing haemostatic material portfolio.

US and EU patents entered national phase 12 January 2023.